La cadena de opciones muestra datos clave de las opciones de acciones de Arcutis Biotherapeutics a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Arcutis Biotherapeutics..

Arcutis Biotherapeutics (NASDAQ:ARQT) Bolsa, Cadena de Opciones

Arcutis Biotherapeutics

Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate ZORYVE roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.

Arcutis Biotherapeutics, Inc. - Common stock

Arcutis Biotherapeutics Inc

FS Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSBW#NASDAQ">FSBW</a>) reported quarterly earnings of $1.29 per share which beat the analyst consensus estimate of $1.14 by 13.16 percent. This is a 14.16 percent increase over earnings of $1.13 per share from the same period last year.

Earnings

Earnings Beats

News

FSBW

FS Bancorp Q3 EPS $1.29 Beats $1.14 Estimate

WIIM

OCUP

Ocuphire Pharma shares are trading higher after the company announced its new OPGx-LCA5 Phase 1/2 6-month data demonstrated safety and visual improvement in its early onset regional degeneration. Also, the company will seek a strategic partner to continue the development of APX3330.

ANRO

Alto Neuroscience shares are trading lower after the company announced topline results from a Phase 2b trial evaluating ALTO-100 as a treatment for major depressed disorder did not meet its primary endpoint.

Southeast Airport Group Q3 2024 GAAP EPS $5.7374 Beats $5.73 Estimate

This closure is part of the Company&rsquo;s Fit to Win initiative to reduce redundant capacity and begin to optimize its network. Additional furnace closures and other restructuring actions are expected later in 2024.
The furnace closure is expected to occur on or after November&nbsp;18, 2024. The Company intends to facilitate the closure in a respectful manner for the approximately 150 people impacted.&nbsp;&nbsp;
Subject to finalization of certain estimates, the Company expects to record a charge associated with this closure of approximately $39 million in the third quarter of 2024.&nbsp; Major components of the charge include approximately $24 million for impairment of plant-related assets, such as the closed furnace and related machinery, and $15 million for one-time employee separation benefits and other costs related to the closing (of which approximately $10 million relate to future cash expenditures).

On October 21, O-I Glass Finalizes Plans For Closure Of A Furnace In Its Americas Segment

Seagate Technology shares are trading lower. The company reported Q1 financial results.

Buybacks

SEIC

SEI Expands Stock Repurchase Program By $400M, Bringing Total Authorization To Approximately $429M

CSGP

CoStar shares are trading lower after the company reported worse-than-expected Q3 revenue results.

Packaging Corp shares are trading higher after the company reported better-than-expected Q3 financial results.

Trustmark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRMK#NASDAQ">TRMK</a>) reported quarterly earnings of $0.84 per share which beat the analyst consensus estimate of $0.82 by 2.44 percent. The company reported quarterly sales of $195.581 million which beat the analyst consensus estimate of $192.457 million by 1.62 percent. This is a 0.73 percent increase over sales of $194.160 million the same period last year.

TRMK

Trustmark Q3 2024 Adj. EPS $0.84 Beats $0.82 Estimate, Sales $195.581M Beat $192.457M Estimate

Franklin Financial Servs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRAF#NASDAQ">FRAF</a>) reported quarterly earnings of $0.95 per share. This is a 7.95 percent increase over earnings of $0.88 per share from the same period last year.

FRAF

Franklin Financial Servs Q3 EPS $0.95 Up From $0.88 YoY

Texas Instruments Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXN#NASDAQ">TXN</a>) reported its third-quarter financial results after Tuesday's closing bell. Here's a look at the <a href="https://www.benzinga.com/pressreleases/24/10/n41465683/ti-reports-third-quarter-2024-financial-results-and-shareholder-returns">details from the report.&nbsp;</a>
The Details: Texas Instruments reported quarterly earnings of $1.47 per share, which beat the analyst consensus estimate of $1.37. Quarterly revenue of $4.151 billion beat the consensus estimate of $4.12 billion.
&#8220;Industrial continued to decline sequentially, while all other end markets grew. Our cash flow from operations of $6.2 billion for the trailing 12 months again underscored the strength of our business model, the quality of our product portfolio and the benefit of 300mm production. Free cash flow for the same period was $1.5 billion,&#8221; said Haviv Ilan, CEO of Texas Instruments.
&#8220;Over the past 12 months we invested $3.7 billion in R&amp;D and SG&amp;A, invested $4.8 billion in capital expenditures and returned $5.2 billion to owners,&#8221; Ilan added.
Read Next: <a href="https://www.benzinga.com/news/24/10/41418987/nuclear-energy-stocks-are-hot-heres-a-list-of-tickers-to-watch">Nuclear Energy Stocks Are Hot: Here&#8217;s A List Of Tickers To Watch</a>
Outlook: Texas Instruments sees fourth-quarter earnings between $1.07 and $1.29 per share, versus the $1.34 estimate and quarterly revenue in a range of $3.7 billion to $4 billion, versus the $4.07 billion consensus estimate. 
TXN Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Texas Instruments shares are seesawing after the close, but at publication on Tuesday were up 0.015% at $194.
Read Also:&nbsp;
<ul>
<li>&nbsp;<a href="https://www.benzinga.com/news/24/10/41415824/lucid-ceo-peter-rawlinson-talks-saudi-investment-elon-musks-political-views-and-taking-business-from">Lucid CEO Peter Rawlinson Talks Saudi Investment, Elon Musk&#8217;s Political Views And Taking Business From Tesla</a></li>
</ul>
Photo: Shutterstock&nbsp;

After-Hours Center

Movers

Tech

Texas Instruments Shares Seesaw After Q3 Results Beat Estimates, Weak Q4 Guidance

The First Bancshares, Inc. ("The First") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FBMS#NYSE">FBMS</a>), holding company for The First Bank, (<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.thefirstbank.com&amp;esheet=54140569&amp;newsitemid=20241022552905&amp;lan=en-US&amp;anchor=www.thefirstbank.com&amp;index=1&amp;md5=48fd2241736b076ad99d73a53a69831d">www.thefirstbank.com</a>), announced today that the previously announced merger between The First and Renasant Corporation ("Renasant"), pursuant to the Agreement and Plan of Merger, dated as of July 29, 2024, (the "Merger Agreement"), has been approved by its shareholders. Completion of the transaction remains subject to customary closing conditions, including the receipt of required regulatory approvals.

FBMS

The First Bancshares Announces Receipt Of Shareholder Approval For Merger

BROS

Dutch Bros shares are trading lower amid sympathy with Starbucks after the company reported Q4 financial results and suspended 2025 guidance.

Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) has outperformed the market over the past 10 years by 18.31% on an annualized basis producing an average annual return of 29.7%. Currently, Tesla has a market capitalization of $696.36 billion. 
Buying $100 In TSLA: If an investor had bought $100 of TSLA stock 10 years ago, it would be worth $1,474.96 today based on a price of $217.98 for TSLA at the time of writing.
<h3>Tesla's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729629259_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

TSLA

$100 Invested In Tesla 10 Years Ago Would Be Worth This Much Today

Kroger will use RFID sensors to enable item-level digital identification for greater inventory accuracy to maximize freshness, reduce waste and optimize associates' time
Avery Dennison (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVY#NYSE">AVY</a>) announced today it will begin working with The Kroger Co. to build a better associate and customer experience through RFID inventory automation technology. This collaboration makes item-level digital identification possible, enabling more frequent and more accurate inventory information to maximize freshness, reduce waste and improve the associate experience.

Avery Dennison Announces It Will Begin Working With The Kroger Co. To Build A Better Associate And Customer Experience Through RFID Inventory Automation Technology

MANH

Manhattan Associates shares are trading lower. The company reported Q3 financial results.

WFRD

Weatherford Q3 Revenue $1.409B; GAAP EPS $2.06 Per Share Vs $1.66 In Q2

PennyMac Financial Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFSI#NYSE">PFSI</a>) reported quarterly earnings of $3.49 per share which beat the analyst consensus estimate of $2.90 by 20.34 percent.

Earnings Misses

PFSI

PennyMac Financial Servs Q3 2024 Adj EPS $3.49 Beats $2.90 Estimate

Bank of N.T Butterfield (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NTB#NYSE">NTB</a>) reported quarterly earnings of $1.16 per share which beat the analyst consensus estimate of $1.14 by 1.75 percent. The company reported quarterly sales of $142.700 million which beat the analyst consensus estimate of $142.472 million by 0.16 percent. This is a 0.71 percent increase over sales of $141.700 million the same period last year.

Bank of N.T Butterfield Q3 2024 Adj. EPS $1.16 Beats $1.14 Estimate, Sales $142.700M Beat $142.472M Estimate

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Align Tech (ALGN – Research Report) and Arcutis Biot...

Analysts Offer Insights on Healthcare Companies: Align Tech (ALGN) and Arcutis Biotherapeutics (ARQT)

Arcutis: Shares Plateau After Early 2024 Gains, But Further Upside Looks Likely

Arcutis surges 18% as Mizuho highlights growth of Zoryve

Arcutis Biotherapeutics (ARQT) has received a new Buy rating, initiated by Jefferies analyst, Kambiz Yazdi. Kambiz Yazdi has given his Buy rating d...

Buy Rating Initiated on Arcutis Biotherapeutics Amidst Zoryve's Market Expansion and Promising Sales Trajectory

With recent top-and-bottom-line beats, biotech Arcutis Biotherapeutics ($ARQT) continues to grab attention as demand for its recently approved trea...

Arcutis Biotherapeutics (ARQT) Riding High on Psoriasis Treatment

Vikram Purohit, an analyst from Morgan Stanley, maintained the Buy rating on Arcutis Biotherapeutics (ARQT – Research Report). The associated price...

Buy Rating Affirmed for Arcutis Biotherapeutics Amid Positive Dermatology Market Signals

Arcutis' supplemental application for Zoryve accepted by FDA

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Bioxcel Therapeutics (BTAI – Research Report) and ...

Analysts Offer Insights on Healthcare Companies: Bioxcel Therapeutics (BTAI) and Arcutis Biotherapeutics (ARQT)

Mizuho Securities analyst Uy Ear maintained a Buy rating on Arcutis Biotherapeutics (ARQT – Research Report) on October 11. The company's shares cl...

Arcutis Biotherapeutics (ARQT) Gets a Buy from Mizuho Securities

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Arcutis Biotherapeutics (ARQT – Research Report) and...

Wall Street Analysts Are Bullish on Top Healthcare Picks

ALGN

ARQT

BTAI

COCH

INCY

ROIV

Health Care

Press Releases

Arcutis to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

Arcutis Announces Positive Long-Term Results of Roflumilast Cream 0.05% Show Durable and Improved Efficacy Over Time and Favorable Safety Profile in Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis

Arcutis Completes Enrollment of Phase 1b Alopecia Areata Study Evaluating ARQ-255

Markets

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Analyst Ratings

Arcutis Announces Publication of ZORYVE® (roflumilast) Cream 0.15% Pivotal Results from Phase 3 INTEGUMENT-1 and -2 Trials in Mild to Moderate Atopic Dermatitis in Journal of American Medical Association Dermatology

FDA Accepts Arcutis' Supplemental New Drug Application for ZORYVE® (roflumilast) Foam for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over

Comments

Arcutis Biotherapeutics

Arcutis Biotherapeutics (ARQT) Opciones

Arcutis Biotherapeutics (NASDAQ:ARQT) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL